*Mage*

1642

PATENT

Case Docket No. MAXIM.026C3
Date: February 19, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hellstrand et al.
Appl. No. : 10/076,306
Filed : February 12, 2002
For : ENHANCED ACTIVATION OF
NATURAL KILLER CELLS
USING AN NK CELL
ACTIVATOR AND A
HYDROGEN PEROXIDE
SCAVENGER OR INHIBITOR
Examiner : Holleran, A.L.
Group Art Unit : 1642

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

February 19, 2004

(Date)


Mallary K. deMerlier, Reg. No. 51,609


TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Mallary K. deMerlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Hellstrand et al.
 App. No. : 10/076,306
 Filed : February 12, 2002
 For : ENHANCED ACTIVATION OF
 NATURAL KILLER CELLS USING AN
 NK CELL ACTIVATOR AND A
 HYDROGEN PEROXIDE SCAVENGER
 OR INHIBITOR
 Examiner : Holleran, Anne L.
 Group Art Unit : 1642

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 4 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/19/04

By: Mallary K. de Merlier

Mallary K. de Merlier
 Registration No. 51,609
 Attorney of Record
 Customer No. 20,995
 (619) 235-8550

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.026C3	APPLICATION NO. 10/076,306
		APPLICANT Hellstrand et al.	
		FILING DATE February 12, 2002	GROUP 1642



U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bacon et al. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. <i>Journal of Experimental Medicine</i> . 181:399-404.
	2	Nelson et al. (1998) Biology of the interleukin-2 receptor. <i>Advances in Immunology</i> . 70:1-81.
	3	Presky et al. (1996) A functional interleukin 12 receptor complex is composed of two β -type cytokine receptor subunits. <i>Proc. Natl. Acad. Sci.</i> 93:14002-14007.
	4	Wolf et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. <i>Journal of Immunology</i> . 146(9):3074-3081.

S:\DOCS\MKD\MKD-4082.DOC\021904

EXAMINER	DATE CONSIDERED
----------	-----------------